Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Neutral 0

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Moderna (MRNA)

📈 Analyst Francois Brisebois from LifeSci Capital maintains a Buy rating on Praxis Precision Medicines with a $567.00 price target.

💰 Praxis shares closed at $344.82, reflecting an 89.2% upside to the analyst consensus price target of $625.31.

⭐ The current consensus for Praxis is Strong Buy with a success rate of 40.4% among Brisebois’s previous calls.

🔄 TipRanks previously upgraded Praxis to Buy on April 15, though Deutsche Bank later raised its target from $412 to $437.

📉 William Blair analyst Myles Minter reiterated a Hold rating for Moderna despite shares closing at $50.73 near their 52-week low of $29.25.

⚠️ Street consensus on Moderna is Hold with an average price target of $38.43, implying a -28.0% downside from current levels.

🔬 Bernstein maintained its Hold rating on Moderna on April 21 with a $45.00 price target to support the neutral sentiment.

💊 Praxis Precision Medicines is advancing its CNS pipeline including an NDA for Ulixacaltamide in Essential Tremor.

✅ The FDA accepted Praxis’s NDA for ulixacaltamide, providing a near-term data catalyst mentioned by analysts.

📊 LifeSci Capital suggests that near-term data and pipeline advancement support the Buy rating despite company cash burn.

Bullish Signals
  • Francois Brisebois from LifeSci Capital maintained a Buy rating on Praxis Precision Medicines (PRAX) with a price target of $567.00, which represents significant upside potential from the current share price of $344.82.
  • The analyst consensus on Praxis Precision Medicines is a Strong Buy with an average price target of $625.31, implying an 89.2% upside from current levels.
  • TipRanks upgraded PRAX to Buy with a $381.00 price target in a report issued on April 15, signaling growing confidence in the stock's performance.
  • William Blair analyst Myles Minter is a 5-star analyst with an average return of 35.4% and a 58.7% success rate, covering Moderna (MRNA).
  • Deutsche Bank raised its Praxis Precision price target to $437 from $412, reflecting positive sentiment among major investment banks.
  • Praxis Precision Medicines received FDA acceptance for ulixacaltamide NDA for Essential Tremor, a key milestone supporting its pipeline advancement.
  • The company is supported by recent Strong Buy ratings from Raymond James and other analysts due to advancing CNS Pipeline and near-term data catalysts.
Risk Factors
  • William Blair analyst Myles Minter reiterated a Hold rating on Moderna today, indicating cautious sentiment from Wall Street.
  • The word on The Street generally suggests a Hold analyst consensus rating for Moderna with a $38.43 average price target, implying a 28.0% downside from current levels.
  • Moderna shares closed last Friday at $50.73, close to its 52-week low of $29.25, suggesting recent significant price weakness and loss of momentum.
Full Analysis
Analysts have provided mixed assessments for healthcare stocks Praxis Precision Medicines (PRAX) and Moderna (MRNA), highlighting divergent market sentiments within the biotechnology sector. LifeSci Capital analyst Francois Brisebois maintained a Buy rating on Praxis Precision Medicines, setting a price target of $567.00 against Friday's closing price of $344.82. Brisebois, a 3-star analyst covering the Healthcare sector, follows other stocks such as Centessa Pharmaceuticals and Aquestive Therapeutics. The consensus outlook for Praxis remains robust, with a Strong Buy rating from analysts and an average price target of $625.31, representing an 89.2% upside potential from current levels. Recent upgrades include a report from April 15 by TipRanks–Google that upgraded the stock to Buy with a $381.00 target, while Deutsche Bank recently raised its price target for Praxis to $437 from $412, citing catalysts from their pipeline. Conversely, Moderna (MRNA) faces significant headwinds according to current analyst consensus, primarily reflected by downgrade sentiments following the COVID-19 pandemic era. William Blair analyst Myles Minter reiterated a Hold rating on Moderna today, noting that shares closed Friday at $50.73, which is near its 52-week low of $29.25. Minter is a highly-rated 5-star analyst covering healthcare names like Contineum Therapeutics and CAMP4 Therapeutics. The general market consensus for Moderna suggests a Hold rating with an average price target of $38.43, implying approximately 28.0% downside from current levels. Bernstein also maintained its Hold rating on the stock in a report issued on April 21 with a price target of $45.00. These contrasting analyst opinions underscore the differing recovery trajectories and investment theses currently applied to small-cap versus large-cap biopharmaceutical companies as of mid-April.